You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations.
Click “OK” to confirm you are a Healthcare Professional.
Hipertenzijai gydyti
„Symplicity Spyral™“ inkstų denervacijos sistema naudojama kaip papildoma priemonė prie medikamentinio gydymo ir gyvenimo būdo pakeitimų. Ši priemonė yra efektyvus ir įrodymais pagrįstas procedūrinis hipertenzijos gydymo metodas.¹⁻⁴
„Symplicity Spyral“ inkstų denervacijos sistema:
SPYRAL HTN-ON MED bandomajame tyrime po trejų metų kraujospūdžio sumažinimas naudojant „Symplicity“ kraujospūdžio procedūrą išlikdavo dieną ir naktį, įskaitant pavojingus laikotarpius vėlai naktį ir anksti ryte, kurie dažniausiai siejami su padidėjusia insulto ir širdies bei kraujagyslių būklių rizika.3
Symplicity Spyral Renal Denervation Procedure - (03:22)
Seen how the Symplicity Spyral renal denervation procedure works to help treat hypertension.
More information (see more)
Less information (see less)
Peržiūrėkite trumpą animaciją, kurioje paaiškinamas RD inkstų denervacijos naudojant „Symplicity Spyral“ sistemą veikimo mechanizmas.
In typical uncontrolled hypertension patients.
ANCOVA adjusted; secondary efficacy analysis.
RDN arm reduction from baseline.
Includes Symplicity Spyral™ and Flex™ catheters.
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. The Lancet. 2020;395:1444–1451.
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet. 2018;391(10137):2346–2355.
Mahfoud F, Mancia G, Schmieder R, et al. Three-year safety and efficacy in the Global Symplicity Registry: Impact of antihypertensive medication burden on blood pressure reduction. Presented at PCR e-course 2020.
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet. 2022;399:1401–1410.
Coates P, Tunev S, Trudel J, et al. Time, temperature, power, and impedance considerations for radiofrequency catheter renal denervation. Cardiovascular Revascularization Medicine. 2022.
Medtronic Data on File.
Medtronic Symplicity Spyral™ Instructions for Use.